Proprietary Global Sourcing Intelligence in an Instant
Decision-makers at CMOs, CDMOs and Bio/Pharma companies rely on Strategic Advantage, to understand industry trends and company capabilities. Quickly get hard-to-find information and benefit from PharmSource’s trademark quantitative approach to analysis. Learn more
CMOs Out in Force at JP Morgan
At the recent JP Morgan conference in San Francisco, I had the chance to talk to contract service providers, CRO presenters and a growing number of CMOs in attendance. M&A involving CMOs and CDMOs was a big topic of discussion. Many of the presenting CMOs claimed..
Outlook for the CMO Industry
The outlook for the contract manufacturing industry is being shaped by several significant trends. The well-financed pipeline makes the near term outlook favorable, but much depends on the number of new approvals for small and mid-size companies. Injectables CMOs should…
Demand and Supply for Contract Manufacturing of Conventional Injectable Drugs Through 2019
This extensive study estimates the demand for contract injectable manufacturing through 2019 and analyzes the supply and demand relationships for these services. Accompanied by a report on the cytotoxic injectable drug outlook, this expert report covers…
Catching a Wave: How Much Will CMOs Benefit From Biosimilars?
Regulatory developments in the United States, coupled with impending patent expiry, have paved the way for the introduction of biosimilars of increasing technical complexity. In the European Union, 20 first wave biosimilars, consisting of…